Broncus lists on the Hong Kong Stock Exchange

The portfolio company of Qiming Venture Partners, Broncus, has been listed on the Hong Kong Stock Exchange. They received Series A funding from the latter in 2014, followed by investing in B and C. Subsequently, this made Qiming the company's largest institutional shareholder. Broncus is a pioneer in the Chinese interventional pulmonology navigation device market, an industry that focuses on lung-mapping technology.

The company went public with an issuing price of $2.40 (HK$18.7) per share. Consequently, this represented a market cap of nearly $1.3 billion (HK$10 billion). This is the ninth public listing from Qiming's portfolio this year, making it a significant success for the VC firm. Broncus CEO Guowei Zhan said that their IPO is "an important milestone for Broncus."

Hong Kong...

Login In


Register now for free access

Notify of
Inline Feedbacks
View all comments